It is estimated that by 2020, Mexico’s total pharmaceutical production will reach $23 billion (increasing by an 8.5 percent compounded annualized rate). While closing the gap, domestic consumption will reach $28 billion thus still requiring imports to meet domestic demand. It is also expected that generic products will keep gaining ground in the domestic market, given the much lower cost and appeal for payers and consumers.
Mexico's marketing authorizations are split between public and private sectors. Heavily state funded medicines in the public sector and private insurance cover roughly 100% of the market. Whereas the market volume is divided evenly between the two sectors the market value of the private sector is about four times the size of the public.
Sample data: Mexico - Venclexta, Venetoclax. Ex-factory, wholesale and retail pricing.